Posology : מינונים

4.2 Posology and method of administration

Posology
Monotherapy for chronic lymphocytic leukaemia

100 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks up to 6 times.
Monotherapy for indolent non-Hodgkin's lymphomas refractory to rituximab 
120 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks for at least 6 times.

Follicular non-Hodgkin’s lymphoma: Combination with rituximab:
The dose is 90 mg/m² body surface area Demustin I.V. on days 1 and 2 plus 375 mg/m² rituximab on day 1; repetition every 4 weeks.


Hepatic impairment
On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impa irment (serum bilirubin < 1.2mg/dl). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2 - 3.0 mg/dl).
No data is available in patients with severe hepatic impairment (serum bilirubin values of > 3.0 mg/dl) (see section   4.3).
Renal impairment
On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of > 10 ml/min. Experience in patients with severe renal impairment is limited.
Paediatric population
The safety and efficacy of bendamustine hydrochloride in children have not yet been established. Current available data is not sufficient to make a recommendation on posology.


Elderly patients
There is no evidence that dose adjustments are necessary in elderly patients (see also section 5.2).
Method of administration
For intravenous infusion over 30 - 60 minutes (see section 6.6).
Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.
Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values dropped to < 3,000/µl or < 75,000/µl, respectively (see section 4.3).
Treatment should be terminated or delayed if leukocyte and/or platelet values dropped to < 3,000/µl or < 75,000/µl, respectively. Treatment can be continued after leukocyte values have increased to > 4,000/µl and platelet values to > 100,000/µl.
The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended (see section 4.4).
In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.
If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.